

# National Board of Examinations

**Question Paper Name :** DrNB Medical Oncology Paper1  
**Subject Name :** DrNB Medical Oncology Paper1  
**Duration :** 180  
**Total Marks :** 100  
**Display Marks:** No

**Maximum Instruction Time :** 0

**Question Number : 1 Question Id : 32718741435 Consider As Subjective : Yes**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Cancer incidence and mortality:

- Measures of burden and measures of risk. [5]
- Discuss the major differences in global and Indian patterns of cancer incidence. [5]

**Question Number : 2 Question Id : 32718741436 Consider As Subjective : Yes**

- Indications that warrant genetic counselling for hereditary cancer syndromes. [5]
- Interpretation of genetic test results and management. [5]

**Question Number : 3 Question Id : 32718741437 Consider As Subjective : Yes**

- a) Differences between Cyberknife and Gamma knife. [5]
- b) Biology of fractionation in radiotherapy. [5]

**Question Number : 4 Question Id : 32718741438 Consider As Subjective : Yes**

- a) Cellular DNA repair pathways. [5]
- b) Concept of synthetic lethality of PARP inhibitors in BRCA mutation. [5]

**Question Number : 5 Question Id : 32718741439 Consider As Subjective : Yes**

- a) L-Asparaginase. [5]
- b) Arsenic trioxide. [5]

**Question Number : 6 Question Id : 32718741440 Consider As Subjective : Yes**

- a) Management of side effects of CART cell therapy. [5]
- b) Principles of Bispecific T-cell engager therapy with an example. [5]

**Question Number : 7 Question Id : 32718741441 Consider As Subjective : Yes**

- a) Discuss molecular classification of endometrial cancer. [5]
- b) Principles of next generation sequencing. [5]

**Question Number : 8 Question Id : 32718741442 Consider As Subjective : Yes**

- a) Real world evidence versus Phase 3 clinical trials. [5]
- b) Discuss concept of hierarchical testing in clinical trials. [5]

**Question Number : 9 Question Id : 32718741443 Consider As Subjective : Yes**

- a) Discuss major differences in HER 2 IHC interpretation between breast and gastric cancer. [5]
- b) Biological and treatment implications of HER 2 mutations and amplifications/over expression. [5]

**Question Number : 10 Question Id : 32718741444 Consider As Subjective : Yes**

- a) Management of constipation in cancer patients. [5]
- b) Immunizations post autologous transplant. [5]